Teva loses patent protection on lucrative MS treatment
August 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis
Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …
FDA says no to Amgen’s Parsabiv
August 25, 2016Research and Development, Sales and Marketing Amgen, FDA, par
Amgen has announced that the US Food and Drug Administration (FDA) has issued a complete response letter rejecting Parsabiv (etelcalcetide) …
Medical device user fees to increase 68% for 2018 to 2022
August 25, 2016Research and Development, Sales and Marketing FDA, Medical device
The Food and Drug Administration has reached an agreement with the medical device industry and laboratory community on proposed recommendations …
Mylan latest target of US anger on drug pricing with EpiPen price increase
August 24, 2016Research and Development, Sales and Marketing Mylan, US, congress, controversy, epipen, price gouging, price increase
The US congress is again subjecting the pharmaceutical industry to heavy scrutiny over drug pricing policies with Mylan its latest …
NICE approves lung cancer and leukaemia treatments
August 24, 2016Research and Development, Sales and Marketing Alimta, CDF, NICE, bosulif, bosutinib, pemetrexed
The National Institute for Health and Care Excellence (NICE) has issued its approval of two drugs for routine use on …
Pfizer to acquire AstraZeneca’s anti-infective business for $550 million upfront
August 24, 2016Research and Development, Sales and Marketing AstraZeneca, Pfizer, Zavicefta, anti-infective
Pfizer has announced that it is to acquire AstraZeneca’s small molecule anti-infective business in a deal potentially worth up to …
NICE recommends Eylea as first-line treatment for sight threatening condition
August 24, 2016Research and Development, Sales and Marketing Bayer, Eylea, NHS, NICE, first-line treatment
Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept) as a cost-effective …
AbbVie’s leukaemia drug granted positive opinion by MHRA through EAMS
August 23, 2016Research and Development, Sales and Marketing
AbbVie’s investigational treatment for chronic lymphocytic leukaemia (CLL) venetoclax has been granted a positive scientific opinion by the Medicines and …
Foundation Medicine adds new immunotherapy features to its gene profiling products
August 23, 2016Manufacturing and Production, Research and Development FoundationOne, oncology, tumour
Foundation Medicine hopes to enhance oncologist insight into potential immunotherapy responses with the addition of new clinical markers to its …
Roche launches ‘next-generation’ blood glucose monitoring system
August 23, 2016Manufacturing and Production, Sales and Marketing Roche, blood glucose monitoring, diabetes
Roche has announced the launch of its new Accu-Chek Guide blood glucose monitoring system. The system promises to simplify everyday …
Bayer’s CRISPR venture opens for business in biotech hub
August 23, 2016Manufacturing and Production, Research and Development Bayer, casebia, crispr, gene editing, gene-editing
Bayer and CRISPR Therapeutics have joined together to launch Casebia Therapeutics and have chosen Cambridge, Massachusetts, as its base to …
Gilead gets EU approval for HIV-prevention treatment Truvada
August 23, 2016Manufacturing and Production, Sales and Marketing EU, Gilead, HIV, PrEP, Truvada, prevention
Gilead Sciences has received marketing authorisation from the European Commission for once-daily Truvada (emtricitabine/tenofovir disoproxil), in combination with safer sex …
Valeant appoints new executive VP of finance and CFO
August 22, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Valeant, appointment
Valeant has announced the appointment of Paul S. Herendeen as executive vice president, who will also take over as chief …
FDA fast tracks Alzheimer’s drug from Lilly, AstraZeneca
August 22, 2016Manufacturing and Production, Research and Development Alzheimer's disease, AstraZeneca, BACE, lilly, phase III
AstraZeneca and Eli Lilly have announced that the US Food and Drug Administration (FDA) has granted AZD3293 its fast track …
Doctors receiving drugmaker payments more likely to prescribe their products, BMJ study finds
August 22, 2016Research and Development, Sales and Marketing
US physicians who received gifts and other payments from drug companies were more likely to prescribe branded anticoagulants and diabetes …
MHRA suspends GMP certificate for Pfizer site in India
August 22, 2016Manufacturing and Production, Sales and Marketing GMP, India, MHRA, Pfizer, ban, facility, import, suspend
The UK’s Medicines and Healthcare Products Agency (MHRA) has recommended that an Indian facility belonging to Pfizer’s Hospira unit be …
FDA delays appraisal of Sanofi, Zealand diabetes drug just days before decision due
August 22, 2016Research and Development, Sales and Marketing NDA, Sanofi, appraisal, diabetes, iglarlixi, type 2, type-2, zealand
There was unfortunate news for Sanofi and Zealand Pharma as the FDA announced that it required additional information, constituting a …
Pfizer acquires Medivation for $14 billion
August 22, 2016Sales and Marketing Medivation, Pfizer, acquisition, oncology
Pfizer has sealed the deal to acquire US cancer drug company Medivation for close to $14 billion in a move …
FDA approves Pfizer’s abuse-deterrent opioid painkiller
August 22, 2016Sales and Marketing FDA, Pfizer, abuse deterrent, abuse-deterrent, approval, opioid, troxyca
Pfizer has announced that the US FDA has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for the …
Top ten stories in the pharmaceutical industry this week
August 19, 2016Medical Communications pharmafile, top ten
The end of another week, and from huge expansions and investments to some shocking and saddening tragedies, it’s been a …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
